Singapore-based startup Oncoshot and internationally recognised contract research organisation (CRO) Novotech have begun a partnership to enhance clinical trial management success.

Novotech, the leading Asia-Pacific (APAC) biotech specialist CRO, presently has offices in 11 geographies across the region, and site partnerships with over 45 key medical institutions.  

As a provider of clinical development services across all clinical trial phases and therapeutic areas, Novotech will leverage the Oncoshot platform to understand matching populations across key clinical trial markets in the APAC region. Oncoshot provides a safe and secure insights-sharing framework where Novotech can conduct feasibilities with data-ready trial sites aggregated on the platform to enable greater ease of engagement and efficiency in starting and conducting clinical trials.

Novotech will be able to access national-level genomic screening partners such as Omico, as well as engage with leading cancer hospitals for feasibilities and continuously refreshed data that will support screening and enrolment throughout the duration of clinical trials.